Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Triolimus||Antimicrotubule Agent 12 HSP90 Inhibitor 35 mTORC1 Inhibitor 8||Triolimus is a composed of a micelle containing the drugs rapamycin, 17-AAG, and paclitaxel, which act synergistically to inhibit tumor growth (PMID: 22896668, PMID: 27365266).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung cancer||not applicable||Triolimus||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Triolimus led to cytotoxicity and inhibited Ras/Raf/MAPK and PI3K/Akt/mTOR pathway signaling in lung cancer cells in culture, and induced apoptosis, which resulted in tumor growth inhibition, in cell line xenograft models (PMID: 22896668).||22896668|
|Unknown unknown||breast cancer||not applicable||Triolimus||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Triolimus led to cytotoxicity and inhbition of Ras/Raf/MAPK and PI3K/Akt/mTOR pathway signaling in breast cancer cells in culture and inhibited tumor growth in cell line xenograft models (PMID: 22896668).||22896668|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|